These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1007 related items for PubMed ID: 10762286
1. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G. Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286 [Abstract] [Full Text] [Related]
2. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G. J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450 [Abstract] [Full Text] [Related]
3. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand. de Herder WW, Reijs AE, Kwekkeboom DJ, Hofland LJ, Nobels FR, Oei HY, Krenning EP, Lamberts SW. Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343 [Abstract] [Full Text] [Related]
4. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A. Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080 [Abstract] [Full Text] [Related]
8. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas. Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G. J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884 [Abstract] [Full Text] [Related]
12. Diagnosis and drug therapy of prolactinoma. Ciccarelli E, Camanni F. Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617 [Abstract] [Full Text] [Related]
15. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Andersen M, Bjerre P, Schrøder HD, Edal A, Høilund-Carlsen PF, Pedersen PH, Hagen C. Clin Endocrinol (Oxf); 2001 Jan; 54(1):23-30. PubMed ID: 11167922 [Abstract] [Full Text] [Related]